The enterovirus 3C protease inhibitor SG85 efficiently blocks rhinovirus replication and is not cross-resistant with rupintrivir

Céline Lacroix, Shyla George, Pieter Leyssen, Rolf Hilgenfeld, Johan Neyts*

*Corresponding author for this work
6 Citations (Scopus)

Abstract

The novel enterovirus protease inhibitor (PI) SG85 effectively inhibits the in vitro replication of 14 rhinoviruses representative of species A and B (median 50% effective concentration, 0.04 μM). A low-level SG85-resistant variant was selected that carried amino acid substitutions S127G and T143A in the 3C protease. Both substitutions are required for low-level resistance to SG85, as demonstrated by reverse genetics. Interestingly, there is no cross-resistance to SG85 and rupintrivir (another PI); a structural explanation is provided for this observation.

Original languageEnglish
JournalAntimicrobial Agents and Chemotherapy
Volume59
Issue number9
Pages (from-to)5814-5818
Number of pages5
ISSN0066-4804
DOIs
Publication statusPublished - 01.09.2015

Fingerprint

Dive into the research topics of 'The enterovirus 3C protease inhibitor SG85 efficiently blocks rhinovirus replication and is not cross-resistant with rupintrivir'. Together they form a unique fingerprint.

Cite this